Publication:
Semaglutide and cardiovascular outcomes in obesity without diabetes

Simple item page
dc.contributor.authorYAVUZ, DİLEK
dc.contributor.authorsYavuz D., Lincoff A. M., Tugce K Oral 1, Marie M Michelsen 1, Jorge Plutzky 1, Christoffer W Tornøe 1, Donna H Ryan 1; K. B. ,. H. M. C. J. D. ,. S. S. E. ,. S. E. S. H. ,. G. K. H. ,. S. E. K. ,. R. F. K. ,. I. L. ,., Trial Investigators S.
dc.date.accessioned2023-12-25T08:34:06Z
dc.date.available2023-12-25T08:34:06Z
dc.date.issued2023-01-01
dc.description.abstractBackground:Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.Methods:In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed.Results:A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).Conclusions:In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number,NCT03574597.).
dc.identifier.citationYavuz D., Lincoff A. M., Tugce K Oral 1, Marie M Michelsen 1, Jorge Plutzky 1, Christoffer W Tornøe 1, Donna H Ryan 1; K. B. ,. H. M. C. J. D. ,. S. S. E. ,. S. E. S. H. ,. G. K. H. ,. S. E. K. ,. R. F. K. ,. I. L. ,., Trial Investigators S., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes", NEW ENGLAND JOURNAL OF MEDICINE, cilt.389, sa.24 , ss.2221-2232, 2023
dc.identifier.doi10.1056/nejmoa2307563
dc.identifier.endpage2232
dc.identifier.issn0028-4793
dc.identifier.issue24
dc.identifier.startpage2221
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/37952131/
dc.identifier.urihttps://hdl.handle.net/11424/295937
dc.identifier.volume389
dc.language.isoeng
dc.relation.ispartofNEW ENGLAND JOURNAL OF MEDICINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Sağlık Meslekleri
dc.subjectPatofizyoloji
dc.subjectTemel Bilgi ve Beceriler
dc.subjectDeğerlendirme ve Teşhis
dc.subjectDahiliye
dc.subjectAile Sağlığı
dc.subjectTıp (çeşitli)
dc.subjectGenel Tıp
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectFundamentals and Skills
dc.subjectAssessment and Diagnosis
dc.subjectInternal Medicine
dc.subjectFamily Practice
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.titleSemaglutide and cardiovascular outcomes in obesity without diabetes
dc.typearticle
dspace.entity.typePublication
local.avesis.idefd4e84a-30be-4cef-a76c-e42ef39f730e
local.indexed.atPUBMED
local.indexed.atWOS
local.indexed.atSCOPUS
relation.isAuthorOfPublication26174ec5-7dca-4038-a7fe-9a43f236fd15
relation.isAuthorOfPublication.latestForDiscovery26174ec5-7dca-4038-a7fe-9a43f236fd15

Files

Collections

Research Outputs